Pressure BioSciences (OTCQB: PBIO), recently announced that SkinScience Labs (“SSL”) has secured an initial $3.5 million order for its premium FDA-registered dermatological hand sanitizer product (http://ibn.fm/KE7x5). A leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions, Pressure BioSciences will acquire SSL through its planned acquisition of Cannaworx, which is expected to close by June 30, 2020. A recent article discussing the company further reads, “The $3.5 million order announced on June 11 is merely the initial order for a four-month supply of the premium, dermatological, hand-sanitizer product. Mr. Morrison expects future orders and other substantial ongoing growth in the hand-sanitizer product area. ‘Since the May 14 announcement that we were entering the multibillion-dollar hand-sanitizer market, I have taken the opportunity to discuss our new, premium-grade, hand-sanitizer product with several large U.S. retail outlets. The reception we received was extremely positive,’ he said.”
To view the full article, visit http://ibn.fm/R94Xs
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
